Interim report
Page 1
Date: November 03, 2026 To, BSE Limited, 20th Floor, P.J. Towers, Dalal Street, Mumbai - 400001. BSE Scrip Code: 544449 National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Scrip Symbol: ANTHEM Subject: Outcome of the Board Meeting held on Tuesday, November 03, 2026 Dear Sir/Ma’am Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”), we would like to inform you that the Board of Directors of Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) ("Company") at their meeting held on Tuesday, November 03, 2026 which commenced at 2.30 p.m. and concluded at 03:45 p.m. have inter -alia, approved the Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of Statutory Auditors for the quarter and half year ended September 30, 2026. The said financials results were duly reviewed and recommended by Audit Committee at its meeting held on same day to the Board. A copy of the said Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Statutory Auditors are enclosed herewith and the extract of the results will be published in the newspapers as required under Regulation 47(1) of SEBI LODR Regulations. The above intimation is also available on the Company’s website at https://anthembio.com/investors/. We request you to kindly take the same on record. Thanking you, Yours truly, For Anthem Biosciences Limited (Formerly known as Anthem Biosciences Private Limited) _____________________ Divya Prasad Company Secretary & Compliance Officer Membership No: A41438
Page 2
S.R. BATLIBOI & ASSOCIATES LLP [y — Chartered Accountants No. 24, Vittal Mallya Road Bengaluru - 560 001, India Tel : 491 80 6648 9000 Independent Auditor’s Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) 1 We have reviewed the accompanying statement of unaudited standalone financial results of Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) (the “Company”) for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the “Statement”) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”). The Company’s Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company’s Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (‘'Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
Page 3
S.R. BATLIBOI & ASSOCIATES LLP Chartered Accountants 5. The comparative financial information of the Company for the quarter ended June 30, 2026, quarter and period ended September 30, 2025, included in these standalone financial results were reviewed by the predecessor auditor and the financial statements of the Company for the year ended March 31,2026, were audited by predecessor auditor who expressed an unmodified conclusion and unmodified opinion on those financial information on July 21, 2026, November 08, 2025 and May 19, 2026 respectively. For S.R. Batliboi & Associates LLP Chartered Accountants ICAI Firm registration number: 101049W /E300004 %&\;\ Q(\. Y\ ety per Rajeev Partner Membership No.: 213803 Unique Document Identification Number: 26 23803 WFZ-X RS 650 Place: Bengaluru Date: November 03, 2026
Page 4
ANTHEM BIOSCIENCES LIMITED (FORMERLY KNOWN AS ANTHEM BIOSCIENCES PRIVATE LIMITED) Corporate 1dentity Number: L24233KA2006PLC039703 Registered and Corporate Office: No 49, ) and F2, Canara Bank Road, Bommasandra Industrial Area, Phase-], Bommasandra, Bangalore-560099 Karnataka India Email ; investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com Statement of Unaudited Standalone Financial Resulls for the Quarter and Half year ended September 30, 2026 (2. in Million) Particulars Quarter ended Half year ended Year ended 30.09.2026 | 30.06.2026 | 30.09.2025 | 30.09.2026 | 30.09.2025 31.03.2026 Unaudited | Unaudited | Unaudited | Unaudited | Unaudited Audited Income Revenue from operations 5,721.08 3,838.42 5,527.03 9,559.50 10,913.71 20,942.99 Other income 646.95 286.00 533.22 932.95 803.93 1,770.88 | Total income 6,368.03 4,124.42 6,060.25 1049245 11,717.64 22,713.87 Expenses Cost of materials consumed 1,934.43 1,449.45 2,037.12 3,383.88 3,661.07 6,967.51 Changes in inventories of finished goods and work-in-progress (109.53) (3.64) 2098 (13317) 90770 986,91 [Employee benefits expense 743.02 727.79 626.33 1,470.81 1,310.41 2,624.63 Finance costs 30.63 763 2256 38.26 39.15 67.08 Depreciation and amortisation expense 22214 223.10 239.20 44524 465.33 995.65 Other expense 506.17 376.49 381.04 882.66 811.58 1,801.25 [ Total expense 3,326.86 2,760.82 3,527.23 6,087.68 7,195.24 13,443.03 Profit before exceptional items and tax 3,041.17 1,363.60 2,533.02 4,404.77 4,522.40 9,270.84 Fxceptional items - = = = : 240.14 Profit before tax 3,041.17 1,363.60 2,533.02 4,404.77 4,522.40 9,030.70 Tax expense | Current tax 81197 347.06 637.51 1,159.03 1,138.20 2,413.05 Adjustment of tax relating to earlier periods 4010 = = 010 2 = Deferred tax credit (19.76) (355 (883) (2331) (8353) 87.99) | Total tax expense 832,31 34351 548.68 1,175.82 1,054.67 2,325.06 Profit for the period/year 2,208.86 1,020.09 1,984.34 3,228.95 3,467.73 6,705.64 (Other comprehensive income/(loss) Items that will not be reclassified subsequently o profit or loss Remeasurement (loss)/gain on defined employee benefit plans (56.51) 937 (1939 (4714 069 (20.09) Income tax ct on above 14.23 (2.36) 4.88 11.87 (0.17) 5.04] (@2.28) 7.01 @@sl) (3527 052 (15.00) Items that will be reclassified subsequently to profit or loss Net (loss)/gain on cash flow hedges 283 5 E > Income tax effect on above ©071) . 212 - - - Other comprehensive income/(loss) for the period/year, net of tax 913 (14.51) (35.27) 052 (15.00) Total comprehensive income for the period/year 2,164.46 1,029.22 1,969.83 3,193.68 3,468.25 6,690.64 Paid-up equity share capital (Nominal value of Rs. 2 each) 1,127.06 1,126.77 112322 1,127.06 1,123.22 1,123.43 Other equity 30,723.58 |Eammtags per share (Nominal value of share Rs. 2 each) (Not annualised except for the year ended March 31, 2026) Basic 392 Lat o VS i Diluted K9 1.80 35 5.69 612 ompaning notes to the Unaudited Standalane Financial Results S acien\ VZS YN < S\ 9> 2R (D7 NG\ 73S el 5 Bangalore = ((“‘}[\Henuamm)fi i A\ Vay/i N\ SN
Page 5
ANTHEM BIOSCIENCES LIMITED (FORMERLY KNOWN AS ANTHEM BIOSCIENCES PRIVATE LIMITED) Corporate Identity Number: 1.24233KA2006PLC039703 Regjstered and Corporate Office: No 49, F1 and F2, Canata Bank Road, Bommasandra Industrial Area, Phase-1, Bommasandra, Bangalore-560009. Karnataka India Email : investors abledanthembio com Telephone: +91 080 6672 4000 Website: wiww.anthembio.com Statement of Standalone Assets and Li; . in Million) Asat Asat Particulars 30.09.2026 31.03.2026 Unaudited Audited T Assets Non-current assets a) Property, plant and equipment 595069 6,096.00 1) Capital work-in-progress 128821 83522 ) Intangible assets 960 436 d) Right-of-use assets 219 2526 €) Financial assets i) Investments 952267 7,175.44 i) Trade receivables 3108 4456 i) Loans 211111 2,02733 iv) Other financial assets 16723 1,63463 1) Deferred tax assels (net) 31156 27638 §) Income tax assets 13204 12857 B) Other non-current assets 38829 17668 Total non-current assets. 2023467 1842443 Current assets a) Inventories, 172219 1,19139 b) Financiel assets i) Ivestments 681872 662565 i) Trade receivables 508578 572933 i) Cash and cash equivalent 19356 12837 iv) Bank balances other than (i) above 659 234 V) Other financial assets 2,93585 255079 <) Other current assets 81535 63616 Total current assets 17,608.12 16,884.03 Total assets 3784279 3530846 I Equity and liabilities Equity ) Equity share capital 1,127.06 112343 b) Other equity 33,0207 3072358 Total equity 3414783 31,847,010 Liabilities Non-current liabilities a) Financial liabilities 19456 28198 1152 883 i) Other financial liabilities 16928 15378 b) Provisions 25387 15519 <) Other non-current liabilities 582 7.00 635.05 606.78 Current liabilities 4) Financial ligbilities i) Borrowings 18974 18974 i) Lease labilities 1358 1973 i) Trade payables - Total ocutstanding dues of micro enterprises and suall] T =l enterprises - Lotal outsanduny, dues of creditors other than nucro entecprises| ey 050 and small enterprises i¥) Other financial liabilitics 20978 21263 1) Other current liabilities 61301 808 9 Provisions 2053 20430 d) Current tax abilities (net) 2201 47305 305991 | 2,854.67 Total equity and liabilities 37,842.79 35,308.46 @ K%enqalurflg / B Aso\ e\ \0\__/5"
Page 6
ANTHEM BIOSCIENCES LIMITED (FORMERLY KNOWN AS ANTHEM BIOSCIENCES PRIVATE LIMITED) Corporate 1dentity Number: 1.24233K A2006PLC039703 Registered and Corporate Office: No 49, F1 and 12, Canara Bank Road, Bommasandra Industrial Area, Phasc-I, Bommasandra, Bangalore-560099. Karnataka India Email : investors abl anthembio.com Telephone Standalone statement of Cash Flows for half year ended Se; +91 080 6672 4000 Website: www anthembio.com (2. in Million) Particulars Tor the half year For the half year ended ended 30.09.2026 30.09.2025 Unaudited Unaudited Cash flows from operating activities: Profit before tax 4,404.77 4,522.40 Adjustments to reconcile profit before tax to net cash flows Depreciation and amortization expense 44524 46533 Interest on term loans 1298 2004 Interest on cash credit loans 076 885 Interest on lease liabilities 108 162 Interest on delayed payment made to MSME vendors 181 590 Bad debls written off - 012 Impairment allowance on trade receivables 3604 ~ Loss on sale of property, plant and equipment 213 000 Inferest income on deposits, bonds and loans to related parties (786.65) (420,06) Gain on sale of investment in mutual funds, net (28.88) (36.86) Fair value gain on financial assels measured at fair value through profit and loss (2862) 7:20) Unrealized foreign exchange (gair)/loss 13218 (13130) Amortization of government grant (117) (117) Share based payment expenses 271 7963 Operating profit before working capital changes 223438 450730 Adjustment for in working capital: (Increase)/decrease in other financial assets 69| 3491 Increase in other assets (223.19) (944.61) Increase in loans (2.27) (817.00) Decrease/ (increase) in trade receivables 52989 (1,208.15) (Increase)/ decrease in inventories (53080) 170731 (Decrease)/ increase in other financial liabilites (48.08)| 3759 Increase/ (decrease) in trade payables 556.66 (363.26) (Decrease)/increase in ofher current labilities (295.43) 1,69784 Increase in provisions 67.76 1333 Cash generated from operating activities 1803 260456 Income taxes paid (net of refunds received) (1,283.63)] (1115.17) Net cash generated from operating activities (A) 299,60 348939 Cash flows from investing act Purchase of properly, plant and equipment, capital work-in-progress and intangible assets (92237) (568.98) Proceeds from sale of property, plant and equipment 139 3754 Redemption in bank deposits (having original maturity of more than 3 months) (net) 112071 8 Redemption/ (investment) in earmarked balances with banks (net) 1564 (675:32) Purchase of investments in other equity instruments (1551 = (Purchase)/redemption of investments (mutual funds, bonds, comumercial papers and debentures) (net) (2466.11) 1.070.63) Interest received 37548 42021 Net cash used in investing activities (B) {1,890.80) (1,857.19) Cash flows from financing activities: Proceeds from exercise of share options 190.04 25519 Repayment of borrowings (101.17) (64.2) Payment of principal portion of lease liabilities 7.63) (6.05) Dividend paid to shareholders (112677) s Net cash (used in)/generated from financing activities (C) (1,045,53) 19492 Net increase in cash and cash equivalents (A+B+C) 6027 182713 Ffect of exchange differences on cash and cash equivalents held in forcign currency a9 @79) Cash and cash equivalents at the begining of the period 12847 DAIRE) Cash and cash equivalents at the end of the period 19356 192447 Components of cash and cash equivalent; Cash on hand 000 0.00 Balances with banks - in curzent accounts 19356 3041 | wse| o &Afl,}\ Se accompaning notes to the Unauditod Standalone Financial Results C[ Bangalore ) - ;\ /:/ /an ((NGM qal W\I:\\\\\ /<)) \\\'vaé N
Page 7
Notes to the Unaudited Standalone Financial Results for the Quarter and Half year ended September 30, 2026 The Unaudited Standalone Financial Results of Anthem Biosciences Limited (the "Company”) have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (“Ind AS”) as prescribed under Section 133 of the| Companics Act, 2013, as amended, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting| principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and| Disclosure Requirements) Regulations 2015 ("SEBI LODR), as amended ("Listing Regulations") These Unaudited Standalone Financial Results have been reviewed by the Audit Committee at its meeting held on November 03, 2026 and approved by the Board of Directors of the Company at its meeting held on November 03, 2026, The Board of Directors of the Company at their meeting held on May 19, 2026 had recommended final dividend for the financial year 2025-26 of] Rs. 2 per share on face value of Rs. 2 each, aggregating to Rs. 1,126.77 million, which was approved at the Annual General Meeting held on July 22, 2026. During the quarter ended June 30, 2026, the Company has allotted 1,670,909 fully paid-up equity shares of Rs. 2 each under the “Anthen| Employee Stock Option Plan 2024” on approval accorded by the Board of Directors of the Company on May 19, 2026 and June 16, 2026, During the quarter ended September 30, 2026, the Company has allotted 143,285 fully paid-up equity shares of Rs. 2 each under the “Anthem| Employee Stock Option Plan 2024” on approval accorded by the Board of Directors of the Company on July 21, 2026 and August 31,2026 Segment information has been presented in the consolidated financial results in accordance with Ind AS 108 notified under Companies (Indian| Accounting Standards) Rules, 2015. The above Unaudited Standalone Financial Results of the Company are available on the Company’s website (www.anthembio.com) and also on| the website of BSE (www.bscindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed. For and on behalf on the Board of Directors of Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) CIN:1.24233K A2006 PLC039703 Ajay Bhardwaj Managing Director DIN: 00333704 Place: Bangalore Date: November 03, 2026
Page 8
S.R. BATLIBOI & ASSOCIATES LLP A8 e Canperra giock Chartered Accountants No. 24, Vittal Mallya Road Bengaluru - 560 001, India Tel : +91 80 6648 9000 Independent Auditor’s Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) ;5 We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) (the “Holding Company”) and its subsidiary (the Holding Company and its subsidiary together referred to as “the Group”) for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the “Statement”) attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”). The Holding Company’s Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company’s Board of Directors . Our responsibility is to express a conclusion on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. The Statement includes the results of the following entities: (i) Anthem Biosciences Limited (i) Neoanthem Lifesciences Private Limited Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (‘'Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
Page 9
S.R. BATLIBOI & ASSOCIATES LLP Chartered Accountants 6. The comparative financial information of the Group for the quarter ended June 30, 2026, quarter and period ended September 30, 2026, included in these consolidated financial results, were reviewed by the predecessor auditor and the Ind AS consolidated financial statements of the Group for the year ended March 31,2026, were audited by predecessor auditor who expressed an unmodified conclusion and unmodified opinion on those consolidated financial information on July 21, 2026, November 08, 2025 and May 19, 2026 respectively. For S.R. Batliboi & Associates LLP Chartered Accountants ICAI Firm registration number: 101049W /E300004 Membership No.: 213803 Unique Document Identification Number: 26213803 TDL T PB84&3 Place: Bengaluru Date: November 03, 2026
Page 10
ANTHEM BIOSCIENCES LIMITED (FORMERLY KNOWN AS ANTHEM BIOSCIENCES PRIVATE LIMITED) Corporate 1dentity Number: L24233KA2006P1C039703 Registered and Corporate Office: No 49, 1 and 12, Canara Bank Road, Bommasandra Industrial Area, Phasc-l, Bommasandsa, Bangalore-560099, Karnataka India timail : investors abléanthembio.com Telephone: +91 080 6672 4000 Website: wwiw.anthembio.com Statement of Unaudited Consolidated nancial Results for the Quarter and Half year ended September 30, 2026 @ in Mill Particulars Quarter ended Half year ended Year ended 30092026 | 30.062026 | 30.09.2025 | 30.09.2026 | 30.09.2025 | 31.03.2026 Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited Income Revenue from operations 594032 418218 550504 1012250 1091371 21,203.19 Other income 588.97 24889 47752 83786 699.06 1,507.97 Total income 652929 443107 598256 1096036 1161277 2280116 Expenses Cost of materials consumed 200773 148563 201263 349336 363468 713592 Changes in inventories of finished goods and work-in-progress (16089) (264 2098 (18459 907.70 986.91 ‘Employee benefits expense 81250 78836 67191 160086 139061 281244 Finance costs 33.10 887 3055 297 47.18 7054 Depreciation and amortisation expense 30711 299.87 33499 606.98 59945 134070 Other expense 566.01 42617 21547 99218 874,64 1,96834 Total expense 356556 298526 3,68653 655082 745426 1431485 Profit before exceptional items and tax 296373 144581 229603 440954 415851 8,486.31 Exceptional items - - - - - 24391 Profit before tax 296373 144581 229603 440950 415851 8,242.40 ‘Tax expense Current tax 81198 347.05 6752 115903 113820 2413.06 Adjustment of tax relating to earlier periods 4010 - - 010 s = Deferred tax credit (298) (10065 (5577) (103:63) (7187) (88:58)| Total tax expense 849.10 24640 56175 109550 106633 232448 Profit for the period/year 211463 119941 173428 331404 309218 5917.92 Other comprehensive incomey/(loss) Items that will not be reclassified subseauently to profit or loss Remeasurement (loss)/ gain on defined employee benefit plans (68.06) 945 (2028) (8.61) 012 (2083) Income tax effect on above 1449 @3 482 1212 (©31) 5.19) @357 708 (1546 (36.49) (0.19) (15.64) Items that will be reclassified subsequently to profit or loss Net (loss)/ gain on cash flow hedges (283) 283 - - S = Income tax effect on abave 071 ©71) - - - - @12) 212 - S 5 3 Other comprehensive income/(loss) for the period/year, net of tax (@5.69) 920 (15.46) (36.49) ©19) 15.64) Total comprehensive income for the period/year 2,068.94 120861 171882 327755 3,091.99 5,902.28 Paid-up equity share capital (Nominal value of Rs. 2 each) 112706 112677 112322 112706 112322 1,123.43 Other equity 2930173 Earnings per share (Nominal value of share Rs. 2 each) (Not annuatised except for the year ended March 31, 2026) Basic V75 213 Diluted iccompaning notes to th naudited Consolidated Financial Re Scwe/, F'[[mmgamre) \%}J
Page 11
ANTHEM BIOSCIENCES LIMITED (FORMERLY KNOWN AS ANTHEM BIOSCIENCES PRIVATE LIMITED) Corporate Identily Number: 124233KA2006PLC039703 Registered and Corporate Office: No 49, FI and F2, Canara Bank Road, Bommasandra Industrial Area, Phase-1, Bommasandra, Bangalote-560099. Kamnataka India. Email : investors abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com Statement of Consolidated Assets and Liabilities . in Million) See accampaning notes to the Unaudited Consolidated Financial Results Asal Asat Particulars 30.09.2026 31.03.2026 Unaudited Audited T Assets Non-current assets a) Property, plant and equipment 7,619.86 7,802.63 1) Capital work-in-progress 3,091.07 264346 ©) Intangible assets 9.63 441 ) Right of use assels 218 2526 ¢ Financial assels i) Investments 5,764.82 341875 i) Trade receivables 2108 3108 iif) Loans 806 7306 iv) Other financial assets 47781 1,64520 f) Deferred tax assets (net) 388.97 7.2 g) Income tax assets 132.04 128.57 h) Other non-current assets 40363 21582 ‘Total non-current assets. 18,054.15 16,261.46 Current assels a) Inventories 1,885.86 124516 b) Financial assets Investments 6,846.71 6,655.87 i) Trade receivables 527238 5,905.88 iii) Cash and cash equ 199.84 169.85 iv) Bank balances other than (iii) above 669 234 V) Other financial assets 293263 255956 ©) Other current assets 166554 147278 ‘Total current assets 18,809.65 18,031.44 | Total assets 36,863.80 34,292.90 1l Equity and liabilties Equity a) Equity share capital 1127.06 112343 b) Other equity 3168279 29,301.73 Total equity 3280985 30,425.16 Liabilities Non-current liabilities ) Financial libilities i) Borrowings 19685 27734 i) Lease liablities 152 883 iii) Other financial liabilities 169.28 153.78 b) Provisions 266,80 16366 ) Other non-current labilities 582 700 ‘Total non-current liabilities 650.27 610.61 Current liabilities a) Financial liabilities i) Borrowings 18974 23334 ii) Lease liabilities 13.58 1973 iif) Trade payables - Total outstanding dues of micro enterprises and small enterprises 9242 10417 - Total outsanding dues of creditors other than micro enterprises anf 155956 - small enterprises iv) Other financial liabilities 336.46 42944 b) Other current liabilities 68938 990 00 q 23053 20966 ) 292,01 37305 Total catrent labilities 3,400.68 325713 Yolal equity and liabilities 3086380 3429290 ((é‘(BE"‘QE‘uru!é‘ 2\
Page 12
ANTHEM BIOSCIENCES LIMITED (FORMERLY KNOWN AS ANTHEM BIOSCIENCES PRIVATE LIMITED) & Registered and Corporate Olfice: No 49, 11 and F2, Canara Bank Road, Bo India porate Identity Number: L24233KA2006P1.C039703 masandra tndus! tal Area, Phase-1, Bommasandra, Bangalore-560099, Karnataka Fanail - investors abli anthembio com Telephone: +91 080 6672 4000 Website: wiww.anthembio com Consolidated statement of Cash Flow for half year ended September 30, 2020 . in Million) Tor the half year | Tor the half year ended ended Farticatars 30.09.2026 30.09.2025 Unaudited Unaudited Cash flows from operating activitics: Profit before tax 140950 415850 Adjustments to reconcile profit before tax (o net cash flows Depreciation and amortization expense 606,98 599,46 Interest on term loans 1298 2004 Interest on cash credit loans 076 885 Interest on lease labilities 1.08 162 Interest on delayed payment made to MSME vendors 398 1379 Bad debis written off i e Impairment allowance on trade recelvables 3604 . Loss on sale of property, plant and equipment 213 = Interest income on deposits, bonds and loans to refated parties (70637) @13.7) Gain on sale of investment in mutual funds, net (3064) (36.86) Fair value gain on financial assols measured at fair value through profit and loss (85) 20) Unrealized foreign exchange (gain)/loss 13241 (131.42) Amortization of government grant 17) (17) Share based payment expenses 27 7963 Operating profit before warking capital changes Sasien 339219 Ad for in ital: Decrease i other financial assels 324 3006 Increase in other assets (206.90) (1,033.7) (Increase)/decrease in loans - (16.61) Decrease/ (ncrease) in trade receivables 50612 (1,106.74) (Increase)/decrease in invenfories (64069) 150675 (Decrease)/increase in other financiallabiltes (18.26) 3750 Increase/ (decreasc) intrade payabies. 3575 (s2184) (Decrease)/increase in other current libilites (340.99) 165173 Increase in provisions 7539 1460 Cash generated from operating activities 34653 5195.06 Income taxes paid (net of refunds received) (1.28363) (1,115.17) Net cash generated from operating activitics (A) 318170 407989 Cash flows from investing acivities: Purchase of property, plant and equipment, capital work-in-progress and intangible assets 105.11) (998.90) Proceds from sale of property, plant and equipment 139 3754 Redemption in bank deposits (having original maturity of more than 3 months) (net) 111980 = Redemption/ (investment) in carmarked balances with banks (net) 1560 (675:32) Purchase of investments n other equity instruments (1554) - (Purchase) redemption of investments (mutual funds, bonds, commercial papers and debentures) (net) (461.92) (1,070.63) Interest received 37360 31318 Net cash used in investing activites (B) @07213) @393.19) Cash flows from financing activities: Proceeds from exercise of share aptions 190.0¢ 25519 Repaymentof borrowings (14013) 123) Payment of principal portion of Iease liabilties 769) (695) Dividend paid to sharcholders (1,12677) : Net cash used in/generated from financing activities (C) ,054.09) 951 Net (decreasel/increase in cash and cash equivalents (A-+B+C) 07 TB8067 Effectof exchange differences on cash and cash equivalents held in foreign currency 10 ) Cash and cash equivalents at the beginning of the period 16985 16143 Cash and cash equivalents at the end of the period 9550 5831 Components of cash and cash equivalint: Cash on hand 001 000 Halances with banks n current accounts 19983 14199 i deposit accaunts with orginal maturity loss than three months) 400 Sewaccompaning notes 1o the Gnaudited Consolidaled Financial Resalts o\ S, K\m( gengaloru 8 | \CAN VA NS~/ & T ¥
Page 13
Notes to the Unaudited Consolidated Financial Results for the Quarter and Half year ended September 30, 2026 I The Unaudited Consolidated Financial Results of Anthem Biosciences Limited (the “ITol ompany”) together with its subsidiary (collectively (he “Group”) have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards as prescribed under Section 133 of the Companics Act, 2013, as amended, read with the Companies (Indian Accounting Standards Rules), 2015, as amended and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR"), as amended (“Listing Regulations”) 2 These Unaudited Consolidated Financial Results have been reviewed by the Audit Committee at its meeting held on November 03, 2026 and approved,| by the Board of Directors of the Holding Company at its meeting held on November 03, 2026. 3 The Board of Directors of the Company at their meeting held on May 19, 2026 had recommended final dividend for the financial year 2025-26 of Rs. 2| per share on face value of Rs. 2 each, aggregating to Rs. 1,126.77 million, which was approved at the Annual General Meeting held on July 22, 2026, 4 During the quarter ended June 30, 2026, the Company has allotted 1,670,909 fully paid-up equity shares of Rs. 2 each under the “Anthem Employee Stack Option Plan 2024” on approval accorded by the Board of Directors of the Company on May 19, 2026 and June 16, 2026. During the quarter ended September 30, 2026, the Company has allotted 143,285 fully paid-up equity shares of Rs. 2 each under the “Anthem) Employee Stock Option Plan 2024” on approval accorded by the Board of Directors of the Company on July 21, 2026 and August 31, 2026, 5 Based on the internal reporting provided to the Chief Operating Decision Maker, the consolidated financial results relate to “Contract Research, Development and Manufacturing Organization (CRDMO)” and “Speciality Ingredients” as the reportable segments of the Group under the provisions| of Ind AS 108 “Operating Segments”. 6 The above Unaudited Consolidated Financial Results of the Company are available on the Company’s website (www.anthembio.com) and also on the| website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed. 5 For and on behalf on the Board of Directors of Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) CIN:L.24233KA2006PLC039703 He A Ajay Bhardwi Managing Director DIN: 00333704 Place: Bangalore Date: November 03, 2026
Page 14
920C ‘50 2qUIPAON 3:20 a10[eBueg 2oe1g £0£66007Td900TVNEETHT T (PoIEIT 21PALI SDUIDSOI WAGUY ST UMOW] A[IULI0]) PAIU] SIHUIDSOL WAYIUY JO SI01231(] JO PIEOG 3Y) BO FPYIG UO P S04 21983 240qe 2 T PASOPSIP 13q 101 94w pakolduua eardes 105 STEIOP 3 ‘20U JUaWEaS DPa O) SANMILT] PUE SIOSSE 53U LO[[e O [ed12eiduwt 5131 ‘a3 sscade f1qeeBueypronur pakoldop U0 372 SRR Pue Sesse Ansean, pue SMIOE) suswdo[aA3p ‘SaRIE) BuumoeIIew Surpnput Auedwo A JO S55e UIeLEd SV 210N 0bThTS_ ISSSID bS60Vy £096CC IBSWE _ €4696C xe) 210594 3j03d [£30L L6426 €871ZT___ VLVOVT __ IVSL6 SCHZT__ SLeLUL U103 910 J0 12U 2MFPRAXD A[GedOf[e-un Pue BTG i55] LEOLUEL _ VEILE9 S9EIS9 WILTE 6LULT 8Ee0F 1oL TES6LT 70898 6v8e8 Eia 7916€ 98067 Suarpasuy Arewads (q QLETL OEEISS 6USSES 0988T LCWET I9TME ONaD (2 ssymsor epuowsos | 11 6IE6CI__ ILEIGOL _ 0SZCLOL__ 0S0SS 8UZ8LY Z£0%6'S 1oL [ SEBLLT 601291 T8 (27 EZ swarpasdu] Aimerads ( 68BLLLL 9ES6Ls 1L00S® [ZTNY T0EWE 6960 ONaD (® sonwsrorjuowSas | | ‘sy[nsa1 pue anuaal o5 JuawSog Daupny | poNpneu(] | poipnedq] | pawipneun | paupneun | paupneus JZTE0TE | SZUC60UE | 9U0C6OVE | SZ0Z600E | OC0Z900E | 9T0T600E Ppapua 1eax ‘papus 1ea4 J[ef] ‘Popue Japen() (worfis ut :2) 207 0 q WO OIqUAEUE MMM VISP 000 Z£99 080 L6+ 2U0YdDa T WOY CIqIBUCRIQE SIOIAAUI | [ “eIpUY eEreIEy, ‘660096-210[eBUCq ‘eXpURSPUILIOG ‘[-35eyd ‘¢aly [PLISIPU] BApuesEuILIOg ‘eoy e EXeued ‘74 e 14 ‘6h ON 2030 aveiodio) pue parisiioy £0L6£0DTAY00ZVIEETHTT H9qunN Auapy esodio) (QALIATT ALVATNd STONIIDSOIE WHHLINY SV NMON ATHTWNO) QALIAIT SIONAIDSOIE WAHINY